Wockhardt receives approval from United States Food & Drug Administration.
M2 EQUITYBITES-September 18, 2012-Wockhardt receives approval from United States Food & Drug Administration(C)2012 M2 COMMUNICATIONS http://www.m2.com
Wockhardt, a pharmaceutical and biotechnology major, announced on Monday that it has received final approval from the United States Food & Drug Administration for its latest anti-ulcer drug.
The company has received approval for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, the generic name for the brand Prevacid, which is used in the treatment of peptic ulcers.
Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO, said "Lansoprazole delayed release formulation is a very challenging product and it once again demonstrates Wockhardt R&D's capability in the NDDS technology space. We have received eight ANDA approvals in the past 30-days and four of them have been products that involved significant technology in formulation."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Sep 18, 2012|
|Previous Article:||Beckera[euro](tm)s Hospital Review honours 100 hospitals.|
|Next Article:||Cablevision names Sandra P Kapell as EVP of Human Resources and Administration.|